1. Home
  2. RCUS vs IRTC Comparison

RCUS vs IRTC Comparison

Compare RCUS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$28.53

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

HOLD

Current Price

$109.46

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCUS
IRTC
Founded
2015
2006
Country
United States
United States
Employees
601
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
RCUS
IRTC
Price
$28.53
$109.46
Analyst Decision
Buy
Strong Buy
Analyst Count
10
13
Target Price
$31.90
$197.92
AVG Volume (30 Days)
1.3M
558.1K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.71
EPS
N/A
N/A
Revenue
$247,000,000.00
$747,138,000.00
Revenue This Year
N/A
$19.60
Revenue Next Year
$45.62
$15.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.24
52 Week Low
$8.84
$100.85
52 Week High
$31.74
$210.01

Technical Indicators

Market Signals
Indicator
RCUS
IRTC
Relative Strength Index (RSI) 51.38 42.72
Support Level $20.20 $101.30
Resistance Level $28.72 $121.88
Average True Range (ATR) 1.33 5.08
MACD -0.16 -1.32
Stochastic Oscillator 50.83 15.50

Price Performance

Historical Comparison
RCUS
IRTC

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

About IRTC iRhythm Technologies Inc.

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Share on Social Networks: